- AstraZeneca (AZN) held talks with Bristol Myers Squibb on a potential merger valuing the combined group near $400B. Discussions ongoing; no deal announced. AZN shares fell ~3% after reports.
- AstraZeneca (AZN) posted 6% revenue growth, driven mainly by oncology sales—key data for traders monitoring AZN's top-line momentum and sector exposure.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.